# US 2026/0137688 A1 · Methods and compositions for inhibition of polymerase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0137688 A1
- Document ID: US20260137688A1
- Status: Published application
- Kind: A1
- Application number: 19/393,999
- Filed: 2025-11-19
- Published: 2026-05-21
- Earliest claimed: 2019-08-16
- Assignees: Island Pharmaceuticals, Ltd.
- Applicants: Island Pharmaceuticals, Ltd.
- Inventors: Shanta Bantia; Pravin L. KOTIAN; Yarlagadda S. BABU
- Web page: https://patentgrep.com/patent/US20260137688A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/215: of carboxylic acids
- A61K 31/351: not condensed with another ring
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- C07D 487/04: Ortho-condensed systems
- C07H 7/06: Heterocyclic radicals
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are methods and compositions for inhibition of viral nucleic acid polymerases, such as RNA and DNA polymerases, and methods and compositions that are useful for treating viral infections in subjects. The methods comprise administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The composition or method may optionally comprise one or more additional anti-viral agents.

## Claims

### Claim 1

A method for treating a viral infection, comprising administering to a human subject in need thereof a therapeutically effective amount of a compound having the following structure:
or a pharmaceutically acceptable salt or hydrate thereof; wherein the virus is a virus of the filoviridae family.

### Claim 2 (depends on 1)

The method of claim 1, wherein the virus is selected from the group consisting of Ebola and Marburg viruses.

### Claim 3 (depends on 2)

The method of claim 2, wherein the virus is Ebola virus.

### Claim 4 (depends on 2)

The method of claim 2, wherein the virus is Marburg virus.

### Claim 5 (depends on 2)

The method of claim 2, further comprising co-administering to the human subject an effective amount of an anti-viral agent.

### Claim 6 (depends on 5)

The method of claim 5, wherein the anti-viral agent is a neuraminidase inhibitor.

### Claim 7 (depends on 5)

The method of claim 5, wherein the anti-viral agent is selected from the group consisting of laninamivir, oseltamivir, zanamivir, and peramivir.

### Claim 8 (depends on 5)

The method of claim 5, wherein the anti-viral agent is peramivir.

### Claim 9 (depends on 2)

The method of claim 2, wherein the compound is administered intravenously, intraperitoneally, intramuscularly, or orally.

### Claim 10

A method for suppressing a viral infection, comprising administering to a human subject in need thereof a therapeutically effective amount of a compound having the following structure:
or a pharmaceutically acceptable salt or hydrate thereof; wherein the virus is a virus of the filoviridae family.

### Claim 11 (depends on 10)

The method of claim 10, wherein the virus is selected from the group consisting of Ebola and Marburg viruses.

### Claim 12 (depends on 11)

The method of claim 11, wherein the virus is Ebola virus.

### Claim 13 (depends on 11)

The method of claim 11, wherein the virus is Marburg virus.

### Claim 14 (depends on 11)

The method of claim 11, further comprising co-administering to the human subject an effective amount of an anti-viral agent.

### Claim 15 (depends on 14)

The method of claim 14, wherein the anti-viral agent is a neuraminidase inhibitor.

### Claim 16 (depends on 14)

The method of claim 14, wherein the anti-viral agent is selected from the group consisting of laninamivir, oseltamivir, zanamivir, and peramivir.

### Claim 17 (depends on 14)

The method of claim 14, wherein the anti-viral agent is peramivir.

### Claim 18 (depends on 11)

The method of claim 11, wherein the compound is administered intravenously, intraperitoneally, intramuscularly, or orally.
